April 27, 2020 / 11:20 AM / a month ago

BRIEF-Harpoon Therapeutics Doses First Patient With HPN217 For Multiple Myeloma

April 27 (Reuters) - Harpoon Therapeutics Inc:

* HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN217, A BCMA TARGETING TRITAC, FOR MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below